Back to search
FDAFDA · Food and drugs·Recall number D-1611-2014

CREON (pancrelipase) Delayed-Release Capsules, Lipase 24,000 USP Units, 250 Capsule Bottles, Rx Only. Marketed by: AbbVie Inc., North Chicago, IL 60064, Product of Germany. NDC 0032-1224-07.

Published October 8, 2014 · Recall initiated: September 15, 2014

Summary

FDA records drug Class II recall D-1611-2014, published October 8, 2014 and initiated September 15, 2014. Recalling firm: AbbVie Inc; Status: Terminated; Reported quantity: 18,021 Bottles; Lot: Lot #: 1020156; Expiry: 3/31/2016. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of Foreign Tablets/Capsules; Presence of co-mingled LipaCreon 13000.

What to do

Voluntary: Firm initiated · Letter

Get an email if CREON has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
CREON
Manufacturer
AbbVie Inc
Distributor
US: Nationwide
UPC
0300322637701
Lot
Lot #: 1020156; Expiry: 3/31/2016
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was CREON (pancrelipase) Delayed-Release Capsules, Lipase 24,000 USP Units, 250 Capsule Bottles, Rx Only. Marketed by: AbbVie Inc., North Chicago, IL 60064, Product of Germany. NDC 0032-1224-07. recalled?

Yes. FDA published recall D-1611-2014 on October 8, 2014. Reported hazard: Presence of Foreign Tablets/Capsules; Presence of co-mingled LipaCreon 13000.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: CREON. UPC: 0300322637701.